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Key Messages
1. In vitro models of well-
differentiated bronchial 
epithelial cells and alveolar type 
II and type I–like pneumocytes 
were set up.
2. The SARS-CoV could 
replicate in well-differentiated 
bronchial epithelial cells and 
alveolar type II pneumocytes 
only.
3. In well-differentiated bronchial 
epithelial cells, type I 
interferons (interferon-beta) 
and cytokine and chemokines 
(eg RANTES, IP-10, IL-6, IL-
8, MCP-1, MIP-1α, MIP-2α) 
were markedly induced after 
infection with SARS-CoV, 
compared to human coronavirus 
HCoV229E and influenza A 
(H1N1) virus.
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Introduction
Severe acute respiratory syndrome (SARS) affected more than 8000 patients in 
over 32 countries. One third of the patients spontaneously recovered early in 
the course of disease; others progressed and about 30% needed intensive care. 
The aetiological agent was the SARS-coronavirus (SARS-CoV).1,2 Experimental 
infection of cynomologous macaques with SARS-CoV reproduced a disease 
with diffuse alveolar damage and multi-nucleate syncytia reminiscent of 
human SARS.3 The SARS-CoV has been demonstrated by reverse transcriptase 
polymerase chain reaction (RT-PCR) and virus isolation in respiratory secretions, 
faeces, urine, and lung biopsy, indicating that SARS-CoV is a disseminated 
infection rather than being restricted to the respiratory tract. 
 The virus antigen can be demonstrated in pneumocytes of SARS patients 
dying within the first 10 days of illness.4 The predominant cells infiltrating the 
alveoli are CD68-positive cells. This suggests that alveolar pneumocytes may be 
the target cells of SARS-CoV and play a role in the pathogenesis of the disease. 
The SARS-CoV cannot replicate in differentiated respiratory epithelial cells or 
in primary non-differentiated bronchial and alveolar epithelial cells, even when 
its functional receptor—ACE2—is present (unpublished data).5 It is therefore 
important to study virus-cell interactions in primary lung alveolar epithelial cells.
 We have established differentiated models of human bronchial epithelial cells 
and have isolated the differentiated status of human types I and II pneumocytes. 
An ex vivo model for lung culture was also established to address the tropism 
and pathogenesis of SARS-CoV in human respiratory epithelial cells.
 We aimed to establish (1) an in vitro model for primary human alveolar 
types I and II epithelial cells (pneumocytes), (2) an in vitro model for well-
differentiated bronchial epithelial cells, and (3) an ex vivo model for SARS-
CoV–infected human lung tissue culture. In addition, we aimed to define the 
gene expression profile (cytokine, chemokine) of primary human respiratory 
epithelial cells infected with SARS-CoV and compare it with human coronavirus 
229E and influenza H1N1 virus. 
Methods
This study was conducted from January 2006 to December 2007. Primary 
human respiratory epithelial cells were infected with SARS-CoV in vitro. Virus 
replication was monitored by measuring the levels of the SARS nucleocapsid 
genes, by immunofluorescence detection of the SARS-CoV nucleoprotein, and 
by titration of the infectious virus. The gene and protein expression profiles 
(cytokine and chemokine) of respiratory epithelial cells infected with SARS-
CoV, human coronavirus 229E, and influenza A (H1N1) virus were compared 
using real-time quantitative RT-PCR.
Results
To evaluate SARS-CoV infection in human respiratory tract, ex vivo models 
for human lung culture and in vitro models for well-differentiated and polarised 
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human respiratory epithelial cells representing the 
bronchial and alveolar epithelial cells were developed (Fig 
1). The tropism of some emerging infectious respiratory 
viruses (eg SARS-CoV, avian and human influenza viruses) 
was investigated using these cultures. The SARS-CoV 
initiated viral gene transcription and protein synthesis 
in well-differentiated bronchial epithelial cells only (Fig 
2) and showed a productive replication in vitro. In well-
differentiated bronchial epithelial cells, type I interferons 
(interferon-beta) and cytokine and chemokines (eg 
RANTES, IP-10, IL-6, IL-8, MCP-1, MIP-1α, MIP-2α) 
were markedly induced after infection with SARS-CoV, 
compared to human coronavirus HCoV229E and influenza 
A (H1N1) virus (Fig 3). However, SARS-CoV was unable 
to infect the alveolar type I-like pneumocytes, but there 
was a very limited infection and abortive productivity 
replication of this virus in type II pneumocytes (Fig 1). 
In an ex vivo experiment for lung culture infection, only 
the alveolar macrophages were infected with SARS-CoV, 
whereas alveolar epithelial cells were uninfected.
Fig 1. Alveolar (a) type I–like and (b) type II pneumocytes infected with SARS-CoV in vitro by H&E staining. (c) ACE2 mRNA 
expression of the alveolar type I-like and type II pneumocytes in vitro from day 0 to 21 in culture. (d) Immunofluorescence 
staining of type II pneumocytes 24 and 48 hours post infection with SARS-CoV and mock infection. The SARS-CoV nucleoprotein 
was stained green with FITC-conjugated mouse anti-NP protein antibody. (e) The virus titre of the supernatant collected from 
SARS-CoV–infected type II pneumocytes from 1 to 144 hours post infection
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Fig 2. Well-differentiated normal human bronchial epithelial (NHBE) cells in vitro cultured in ALI for 28 days 
(a) ACE2 mRNA expression of the well-differentiated NHBE cells from day 0 to 28 in air-liquid interface culture. (b) Immunofluorescence 
staining of well-differentiated NHBE cells 48 and 120 hours post infection with SARS-CoV and mock infection. The SARS-CoV 
nucleoprotein was stained green with FITC-conjugated mouse anti-NP protein antibody. (c) The virus titre of the supernatant collected 
and the mRNA expression of SARS-CoV nucleocapsid gene from SARS-CoV–infected well-differentiated NHBE cells from 1 to 168 hours 
post infection
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Conclusions
Type II pneumocytes and well-differentiated bronchial 
epithelial cells can be infected with SARS-CoV but in 
vitro productive infectivity was not shown with alveolar 
type I-like pneumocytes and non-differentiated bronchial 
epithelial cells. The in vitro model enables a better 
understanding of how human respiratory epithelium 
responds to SARS-CoV and other respiratory viruses in 
order to better deal with other emerging infections such 
as avian influenza H5N1 virus. It also helps elucidate the 
underlying mechanism of inter-species transmission of 
animal pathogens to humans. Besides, SARS-CoV showed 
limited tissue tropism for human respiratory tract in vitro 
(infection and replication demonstrated only in well-
differentiated bronchial epithelial cells). Therefore, it is 
important to use the appropriate in vitro human respiratory 
model to study the pathogenesis of SARS-CoV. 
 The host innate immune response induced by the 
SARS-CoV infection can elicit strong induction of an 
IFN response in human well-differentiated bronchial 
epithelial cells. In contrast to the low pathogenicity of 
HCoV 229E and influenza H1N1 viruses, SARS-CoV can 
trigger the release of certain cytokines and chemokines in 
respiratory epithelium. The differential hyper-induction 
of cytokines plays an important role in human infection 
with SARS-CoV. Comparison of the gene expression 
profile of SARS-CoV with the profiles of other highly 
pathogenic viruses (such as H5N1) may provide further 
insight into host molecular mechanisms involving viral 
pathogenicity.
Implications
In vitro and ex vivo studies of the tissue tropism of SARS-
CoV can be extended to other emerging respiratory viruses 
that target human respiratory epithelial cells, especially 
H5N1 and/or H1N1 viruses. Such studies can be used to 
characterise and isolate emerging respiratory viruses that 
are difficult to culture in the laboratory (eg coronavirus 
HKU1) using transformed cell lines.
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Fig 3. The cytokine and chemokine mRNA expression profile, IFN-β, IP-10, RANTES, MCP-1, MIP-1α, MIP-2α, IL-6, and IL-8 
gene expression of the well-differentiated normal human bronchial epithelial cells 0, 24, 48, and 72 hours post infection of 
SARS-CoV, HCoV 229E, and influenza H1N1 virus. The means and standard errors of three representative experiments are 
shown. 
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 The host innate immune response–related gene 
expression profiling of respiratory epithelial cells infected 
with SARS-CoV has provided information about a group 
of cytokine and chemokine genes that may be involved in 
its pathogenicity. Our in vitro and ex vivo models enable 
studying the tropism and pathogenesis of SARS-CoV, 
especially when suitable small animal models adhering 
to the 3R principles on the use of animals in research are 
lacking. 
 Our study focused on one key component of the innate 
immune response—the respiratory epithelium. Further 
investigations of this hypothesis with relevant animal 
models of SARS could also be considered. In vitro, the 
SARS-CoV is highly susceptible to the antiviral effects of 
IFN-ß. In studies on primates, IFN therapy (in combination 
with steroids) is beneficial for both prophylaxis and early 
therapy. Our results may provide a biological basis for the 
observed therapeutic benefit with IFNs in SARS patients 
when administered early.
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